Inhibition of HIV-1 replication by RNA-based strategies

Current HIV Research

Volumn 6, Issue 6, 2008, Pages 500-514

  Reyes Darias, José A ^a   Sánchez Luque, Francisco J ^a   Berzal Herranz, Alfredo ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Antisense RNAs; HIV 1; Ribozymes; RNA aptamers; RNA therapies; Small interfering RNAs

Indexed keywords

APTAMER; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COMPLEMENTARY RNA; DECOY RNA; GENOMIC RNA; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; LENTIVIRUS VECTOR; MESSENGER RNA; NEF PROTEIN; RETROVIRUS VECTOR; RIBONUCLEASE; RIBONUCLEASE P; RIBOZYME; RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SMALL NUCLEAR RNA; TRANSACTIVATOR PROTEIN; TRANSFER RNA; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; VIRUS RNA;

ANTIVIRAL ACTIVITY; BINDING SITE; CLINICAL TRIAL; DRUG TARGETING; GENE DELETION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PROTEIN RNA BINDING; RECEPTOR BINDING; REVERSE TRANSCRIPTION; REVIEW; RNA CLEAVAGE; RNA INTERFERENCE; RNA TRANSLATION; VIRUS ATTACHMENT; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REPLICATION; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY;

ANTIVIRAL AGENTS; HIV-1; HUMANS; RNA; RNA, VIRAL; VIRUS REPLICATION;

EID: 58149214288     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208786501454     Document Type: Review

References (181)

1. Coffin JM. Retroviridae: The virus and their replication. In: Fields BN, Knipe DM, Howloy PM, Eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven 1996; pp. 1767-830.
2. Trono D. HIV accessory proteins: leading roles for the supporting cast. Cell 1995; 82: 189-92.
3. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unravelling viral and host cell biology. Science 1998; 280: 1880-4.
4. Freed EO, Martin MA. HIVs and their Replication. In: Knipe DM, Howley PM, Eds. Fields Virology. 5th ed. Phliladelphia: Wolters kluwer Lippincott Williams & Wilkins 2007; pp. 2107-85.
5. Rabson AB, Braves BJ. Synthesis and processing of viral RNA. In: Coffin JM, Hughes SH, Varmus HE, Eds. Retrovirus. New York: Cold Spring Harbor Laboratory Press 1997; pp. 205-61.
6. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
7. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224: 500-3.
8. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007; 6: 1001-18.
9. Brenner B, Wainberg MA, Salomon H, et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents 2000; 16: 429-34.
10. Si-Mohamed A, Kazatchkine MD, Heard I, et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000; 182: 112-22.
11. Dorman KS, Kaplan AH, Lange K, Sinsheimer JS. Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1? J Acquir Immune Defic Syndr 2000; 25: 398-402.
12. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-7.
13. Scherer L, Rossi JJ, Weinberg MS. Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 2007; 14: 1057-64.
14. Dorman N, Lever AM. RNA-based gene therapy for HIV infection. HIV Med 2001; 2: 114-22.
15. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol 2007; 25: 1444-54.
16. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990; 249: 1533-44.
17. Cech TR. The chemistry of self-splicing RNA and RNA enzymes. Science 1987; 236: 1532-9.
18. Tanner NK. Ribozymes: the characteristics and properties of catalytic RNAs. FEMS Microbiol Rev 1999; 23: 257-75.
19. Puerta-Fernandez E, Romero-Lopez C, Barroso-delJesus A, Berzal-Herranz A. Ribozymes: recent advances in the development of RNA tools. FEMS Microbiol Rev 2003; 27: 75-97.
20. Hampel A, Tritz R. RNA catalytic properties of the minimum (-)sTRSV sequence. Biochemistry 1989; 28: 4929-33.
21. Berzal-Herranz A, Joseph S, Chowrira BM, Butcher SE, Burke JM. Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. EMBO J 1993; 12: 2567-73.
22. Forster AC, Symons RH. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 1987; 49: 211-20.
23. Kore AR, Vaish NK, Kutzke U, Eckstein F. Sequence specificity of the hammerhead ribozyme revisited; the NHH rule. Nucleic Acids Res 1998; 26: 4116-20.
24. Zoumadakis M, Tabler M. Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes. Nucleic Acids Res 1995; 23: 1192-6.
25. Chowrira BM, Berzal-Herranz A, Burke JM. Novel guanosine requirement for catalysis by the hairpin ribozyme. Nature 1991; 354: 320-2.
26. Perez-Ruiz M, Barroso-DelJesus A, Berzal-Herranz A. Specificity of the hairpin ribozyme. Sequence requirements surrounding the cleavage site. J Biol Chem 1999; 274: 29376-80.
27. Pinard R, Lambert D, Walter NG, Heckman JE, Major F, Burke JM. Structural basis for the guanosine requirement of the hairpin ribozyme. Biochemistry 1999; 38: 16035-9.
28. Altman S, Kirsebom L, Talbot S. Recent studies of ribonuclease P. FASEB J 1993; 7: 7-14.
29. Altman S, Baer MF, Bartkiewicz M, et al. Catalysis by the RNA subunit of RNase P - a minireview. Gene 1989; 82: 63-4.
30. Forster AC, Altman S. External guide sequences for an RNA enzyme. Science 1990; 249: 783-6.
31. Yuan Y, Hwang ES, Altman S. Targeted cleavage of mRNA by human RNase P. Proc Natl Acad Sci USA 1992; 89: 8006-10.
32. Biasolo MA, Radaelli A, Del Pup L, Franchin E, De Giuli-Morghen C, Palu G. A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection. J Virol 1996; 70: 2154-61.
33. Liu D, Donegan J, Nuovo G, Mitra D, Laurence J. Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA. J Virol 1997; 71: 4079-85.
34. Veres G, Escaich S, Baker J, et al. Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes. J Virol 1996; 70: 8792-800.
35. Veres G, Junker U, Baker J, et al. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J Virol 1998; 72: 1894-901.
36. Cohli H, Fan B, Joshi RL, Ramezani A, Li X, Joshi S. Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s). Antisense Res Dev 1994; 4: 19-26.
37. Ding SF, Noronha J, Joshi S. Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication. Nucleic Acids Res 1998; 26: 3270-8.
38. Sorrentino S, Libonati M. Structure-function relationships in human ribonucleases: main distinctive features of the major RNase types. FEBS Lett 1997; 404: 1-5.
39. Mautino MR. Lentiviral vectors for gene therapy of HIV-1 infection. Curr Gene Ther 2002; 2: 23-43.
40. Doudna JA, Cech TR, Sullenger BA. Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci USA 1995; 92: 2355-9.
41. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 505-10.
42. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007; 14: 283-91.
43. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990; 63: 601-8.
44. Lee SW, Gallardo HF, Gaspar O, Smith C, Gilboa E. Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther 1995; 2: 377-84.
45. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 1991; 65: 6811-6.
46. Kohn DB, Bauer G, Rice CR, et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999; 94: 368-71.
47. Bauer G, Selander D, Engel B, et al. Gene therapy for pediatric AIDS. Ann N Y Acad Sci 2000; 918: 318-29.
48. Peng H, Callison DE, Li P, Burrell CJ. Enhancement or inhibition of HIV-1 replication by intracellular expression of sense or antisense RNA targeted at different intermediates of reverse transcription. AIDS 1997; 11: 587-95.
49. Sajic R, Lee K, Asai K, et al. Use of modified U1 snRNAs to inhibit HIV-1 replication. Nucleic Acids Res 2007; 35: 247-55.
50. Asparuhova MB, Marti G, Liu S, Serhan F, Trono D, Schumperli D. Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping. J Gene Med 2007; 9: 323-34.
51. Liu S, Asparuhova M, Brondani V, Ziekau I, Klimkait T, Schumperli D. Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Res 2004; 32: 3752-9.
52. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
53. Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001; 2: 110-9.
54. Devroe E, Silver PA. Retrovirus-delivered siRNA. BMC Biotechnol 2002; 2: 15.
55. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006-10.
56. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 1443-8.
57. Adelson ME, Martinand-Mari C, Iacono KT, Muto NF, Suhadolnik RJ. Inhibition of human immunodeficiency virus (HIV-1) replication in SupT1 cells transduced with an HIV-1 LTR-driven PKR cDNA construct. Eur J Biochem 1999; 264: 806-15.
58. Brand SR, Kobayashi R, Mathews MB. The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR. J Biol Chem 1997; 272: 8388-95.
59. Muto NF, Martinand-Mari C, Adelson ME, Suhadolnik RJ. Inhibition of replication of reactivated human immunodeficiency virus type 1 (HIV-1) in latently infected U1 cells transduced with an HIV-1 long terminal repeat-driven PKR cDNA construct. J Virol 1999; 73: 9021-8.
60. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003; 77: 11531-5.
61. Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78: 2601-5.
62. Sabariegos R, Gimenez-Barcons M, Tapia N, Clotet B, Martinez MA. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol 2006; 80: 571-7.
63. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47: 333-48.
64. Bour S, Geleziunas R, Wainberg MA. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev 1995; 59: 63-93.
65. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85(7):1135-48.
66. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
67. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-81.
68. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. Nature 1998; 391: 240.
69. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44: 591-5.
70. Collman R, Balliet JW, Gregory SA, et al. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 1992; 66: 7517-21.
71. Sattentau QJ, Moore JP. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991; 174: 407-15.
72. Thali M, Moore JP, Furman C, et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993; 67: 3978-88.
73. Nielsen MH, Pedersen FS, Kjems J. Molecular strategies to inhibit HIV-1 replication. Retrovirology 2005; 2: 10.
74. Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8: 681-6.
75. Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ. Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther 2004; 11: 1703-12.
76. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-62.
77. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-3.
78. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
79. Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 1998; 95: 9448-53.
80. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44 (6):1667-73.
81. Qureshi A, Zheng R, Parlett T, et al. Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA. Biochem J 2006; 394: 511-8.
82. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 2000; 1: 244-54.
83. Goila R, Banerjea AC. Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme. FEBS Lett 1998; 436: 233-8.
84. Gonzalez MA, Serrano F, Llorente M, Abad JL, Garcia-Ortiz MJ, Bernad A. A hammerhead ribozyme targeted to the human chemokine receptor CCR5. Biochem Biophys Res Commun 1998; 251: 592-6.
85. Anderson J, Banerjea A, Akkina R. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 2003; 13: 303-12.
86. Martinez MA, Gutierrez A, Armand-Ugon M, et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002; 16: 2385-90.
87. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-8.
88. Khati M, Schuman M, Ibrahim J, Sattentau Q, Gordon S, James W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J Virol 2003; 77: 12692-8.
89. Dey AK, Khati M, Tang M, Wyatt R, Lea SM, James W. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J Virol 2005; 79: 13806-10.
90. Park WS, Miyano-Kurosaki N, Hayafune M, et al. Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. Nucleic Acids Res 2002; 30: 4830-5.
91. Lori F, di Marzo Veronese F, de Vico AL, Lusso P, Reitz MS Jr, Gallo RC. Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol 1992; 66: 5067-74.
92. Stevenson M, Haggerty S, Lamonica CA, Meier CM, Welch SK, Wasiak AJ. Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J Virol 1990; 64: 2421-5.
93. Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 1995; 69: 376-86.
94. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990; 9: 1551-60.
95. Wu Y, Marsh JW. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 2001; 293: 1503-6.
96. Wu Y, Marsh JW. Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J Virol 2003; 77: 10376-82.
97. Wu Y. HIV-1 gene expression: lessons from provirus and nonintegrated DNA. Retrovirology 2004; 1: 13.
98. Lys3-ribozyme chimeric RNAs inhibits HIV infection. Antisense Nucleic Acid Drug Dev 1998; 8: 185-97.
99. Kechli AM, Freiden PJ, Rossi JJ, et al. Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication. Hum Gene Ther 1998; 9: 587-90.
100. His as the HIV reverse transcription primer. Virol J 2007; 4: 4.
101. Han W, Wind-Rotolo M, Kirkman RL, Morrow CD. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site. Virology 2004; 330: 221-32.
102. Hnatyszyn H, Spruill G, Young A, Seivright R, Kraus G. Longterm RNase P-mediated inhibition of HIV-1 replication and pathogenesis. Gene Ther 2001; 8: 1863-71.
103. Westerhout EM, ter Brake O, Berkhout B. The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology 2006; 3: 57.
104. Arya SK, Guo C, Josephs SF, Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985; 229: 69-73.
105. Feng S, Holland EC. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 1988; 334: 165-7.
106. Parada CA, Roeder RG. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxyterminal domain. Nature 1996; 384: 375-8.
107. Herrmann CH, Rice AP. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol 1995; 69: 1612-20.
108. Brady J, Kashanchi F. Tat gets the "green" light on transcription initiation. Retrovirology 2005; 2: 69.
109. Lisziewicz J, Sun D, Smythe J, et al. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 1993; 90: 8000-4.
110. Chang HK, Gendelman R, Lisziewicz J, Gallo RC, Ensoli B. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1. Gene Ther 1994; 1: 208-16.
111. Barroso-DelJesus A, Puerta-Fernandez E, Tapia N, et al. Inhibition of HIV-1 replication by an improved hairpin ribozyme that includes an RNA decoy. RNA Biol 2005; 2: 75-9.
112. Bohjanen PR, Liu Y, Garcia-Blanco MA. TAR RNA decoys inhibit tat-activated HIV-1 transcription after preinitiation complex formation. Nucleic Acids Res 1997; 25: 4481-6.
113. Michienzi A, Li S, Zaia JA, Rossi JJ. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci USA 2002; 99: 14047-52.
114. Barnor JS, Miyano-Kurosaki N, Yamaguchi K, Abumi Y, Ishikawa K, Yamamoto N. Lentiviral-mediated delivery of combined HIV-1 decoy TAR and Vif siRNA as a single RNA molecule that cleaves to inhibit HIV-1 in transduced cells. Nucleosides Nucleotides Nucleic Acids 2005; 24: 431-4.
115. Berkhout B, Vastenhouw NL, Klasens BI, Huthoff H. Structural features in the HIV-1 repeat region facilitate strand transfer during reverse transcription. RNA 2001; 7: 1097-114.
116. Longchuan B, Jiangang Y, Guangwei D, Quanbi Z, Yiming S, Boqin Q. Intracellular expression of multimerized antisense TARCore RNAs inhibit the replication of human immunodeficiency virus type 1 in human CD4+ T lymphocytes. Chin Med Sci J 1999; 14: 13-6.
117. Chuah MK, Vandendriessche T, Chang HK, Ensoli B, Morgan RA. Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. Hum Gene Ther 1994; 5: 1467-75.
118. Puerta-Fernandez E, Barroso-del Jesus A, Romero-Lopez C, Tapia N, Martinez MA, Berzal-Herranz A. Inhibition of HIV-1 replication by RNA targeted against the LTR region. AIDS 2005; 19: 863-70.
119. Coburn GA, Cullen BR. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 2002; 76: 9225-31.
120. ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 2006; 14: 883-92.
121. Liu YP, Haasnoot J, Ter Brake O, Berkhout B, Konstantinova P. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 2008; 36(9): 2811-24.
122. Sood V, Unwalla H, Gupta N, Chakraborti S, Banerjea AC. Potent knock down of HIV-1 replication by targeting HIV-1 Tat/Rev RNA sequences synergistically with catalytic RNA and DNA. AIDS 2007; 21: 31-40.
123. Unwalla H, Chakraborti S, Sood V, Gupta N, Banerjea AC. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget antiTAT/ Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme. Antiviral Res 2006; 72: 134-44.
124. Purvis SF, Jacobberger JW, Sramkoski RM, Patki AH, Lederman MM. HIV type 1 Tat protein induces apoptosis and death in Jurkat cells. AIDS Res Hum Retroviruses 1995; 11: 443-50.
125. Meyaard L, Otto SA, Schuitemaker H, Miedema F. Effects of HIV-1 Tat protein on human T cell proliferation. Eur J Immunol 1992; 22: 2729-32.
126. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993; 262: 1011-8.
127. Ikeda M, Habu Y, Miyano-Kurosaki N, Takaku H. Suppression of HIV-1 replication by a combination of endonucleolytic ribozymes (RNase P and tRNnase ZL). Nucleosides Nucleotides Nucleic Acids 2006; 25: 427-37.
128. Rhodes A, James W. Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA. J Gen Virol 1990; 71: 1965-74.
129. Sundquist WI. Tattle tales. Nat Struct Biol 1996; 3: 8-11.
130. Wyszko E, Barciszewska MZ, Bald R, Erdmann VA, Barciszewski J. The specific hydrolysis of HIV-1 TAR RNA element with the anti-TAR hammerhead ribozyme: structural and functional implications. Int J Biol Macromol 2001; 28: 373-80.
131. Cullen BR, Greene WC. Regulatory pathways governing HIV-1 replication. Cell 1989; 58: 423-6.
132. Kjems J, Askjaer P. Rev protein and its cellular partners. Adv Pharmacol 2000; 48: 251-98.
133. Vagner S, Ruegsegger U, Gunderson SI, Keller W, Mattaj IW. Position-dependent inhibition of the cleavage step of pre-mRNA 3′end processing by U1 snRNP. RNA 2000; 6: 178-88.
134. Zhou C, Bahner IC, Larson GP, Zaia JA, Rossi JJ, Kohn EB. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 1994; 149: 33-9.
135. Yamada O, Kraus G, Leavitt MC, Yu M, Wong-Staal F. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells. Virology 1994; 205: 121-6.
136. Junker U, Rittner K, Homann M, Bevec D, Bohnlein E, Sczakiel G. Reduction in replication of the human immunodeficiency virus type 1 in human T cell lines by polymerase III-driven transcription of chimeric tRNA-antisense RNA genes. Antisense Res Dev 1994; 4: 165-72.
137. Cagnon L, Cucchiarini M, Lefebvre JC, Doglio A. Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 349-58.
138. Peng H, Callison D, Li P, Burrell C. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector. Virology 1996; 220: 377-89.
139. Prater CE, Saleh AD, Wear MP, Miller PS. Allosteric inhibition of the HIV-1 Rev/RRE interaction by a 3′-methylphosphonate modified antisense oligo-2′-O-methylribonucleotide. Oligonucleotides 2007; 17: 275-90.
140. Konopka K, Lee NS, Rossi J, Duzgunes N. Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication. Gene 2000; 255: 235-44.
141. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002; 20: 500-5.
142. Balvay L, Lopez Lastra M, Sargueil B, Darlix JL, Ohlmann T. Translational control of retroviruses. Nat Rev Microbiol 2007; 5: 128-40.
143. Hotchkiss G, Maijgren-Steffensson C, Ahrlund-Richter L. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites. Mol Ther 2004; 10: 172-80.
144. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F, Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci USA 1992; 89: 10802-6.
145. Barnor JS, Endo Y, Habu Y, et al. Effective inhibition of HIV-1 replication in cultured cells by external guide sequences and ribonuclease P. Bioorg Med Chem Lett 2004; 14: 4941-4.
146. Foster JL, Garcia JV. Role of Nef in HIV-1 replication and pathogenesis. Adv Pharmacol 2007; 55: 389-409.
147. Herbein G, Khan KA. Is HIV infection a TNF receptor signallingdriven disease? Trends Immunol 2008; 29: 61-7.
148. Konstantinova P, de Vries W, Haasnoot J, ter Brake O, de Haan P, Berkhout B. Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA. Gene Ther 2006; 13: 1403-13.
149. Konstantinova P, ter Brake O, Haasnoot J, de Haan P, Berkhout B. Trans-inhibition of HIV-1 by a long hairpin RNA expressed within the viral genome. Retrovirology 2007; 4: 15.
150. Yamamoto T, Miyoshi H, Yamamoto N, Inoue J, TsunetsuguYokota Y. Lentivirus vectors expressing short hairpin RNAs against the U3-overlapping region of HIV nef inhibit HIV replication and infectivity in primary macrophages. Blood 2006; 108: 3305-12.
151. Omoto S, Fujii YR. Cloning and detection of HIV-1-encoded microRNA. Methods Mol Biol 2006; 342: 255-65.
152. Bennasser Y, Le SY, Yeung ML, Jeang KT. MicroRNAs in human immunodeficiency virus-1 infection. Methods Mol Biol 2006; 342: 241-53.
153. Mattes J, Yang M, Foster PS. Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function? Am J Respir Cell Mol Biol 2007; 36: 8-12.
154. Cullen BR. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 1992; 56: 375-94.
155. Mouland AJ, Mercier J, Luo M, Bernier L, DesGroseillers L, Cohen EA. The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation. J Virol 2000; 74: 5441-51.
156. Marquet R, Paillart JC, Skripkin E, Ehresmann C, Ehresmann B. Dimerization of human immunodeficiency virus type 1 RNA involves sequences located upstream of the splice donor site. Nucleic Acids Res 1994; 22: 145-51.
157. Paillart JC, Marquet R, Skripkin E, Ehresmann B, Ehresmann C. Mutational analysis of the bipartite dimer linkage structure of human immunodeficiency virus type 1 genomic RNA. J Biol Chem 1994; 269: 27486-93.
158. Skripkin E, Paillart JC, Marquet R, Ehresmann B, Ehresmann C. Identification of the primary site of the human immunodeficiency virus type 1 RNA dimerization in vitro. Proc Natl Acad Sci USA 1994; 91: 4945-9.
159. Lever A, Gottlinger H, Haseltine W, Sodroski J. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 1989; 63: 4085-7.
160. Andersen ES, Contera SA, Knudsen B, Damgaard CK, Besenbacher F, Kjems J. Role of the trans-activation response element in dimerization of HIV-1 RNA. J Biol Chem 2004; 279: 22243-9.
161. Skripkin E, Paillart JC, Marquet R, Blumenfeld M, Ehresmann B, Ehresmann C. Mechanisms of inhibition of in vitro dimerization of HIV type I RNA by sense and antisense oligonucleotides. J Biol Chem 1996; 271: 28812-7.
162. Chadwick DR, Lever AM. Antisense RNA sequences targeting the 5′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Ther 2000; 7: 1362-8.
163. Gu S, Ji J, Kim JD, Yee JK, Rossi JJ. Inhibition of infectious human immunodeficiency virus type 1 virions via lentiviral vector encoded short antisense RNAs. Oligonucleotides 2006; 16: 287-95.
164. Kitano M, Barnor JS, Miyano-Kurosaki N, et al. Effective suppression of HIV-1 gene expression by a mammalian tRNA 3′ processing endoribonuclease and external guide sequence oligozymes. Nucleosides Nucleotides Nucleic Acids 2001; 20: 719-22.
165. Yukita M, Kitano M, Miyano-Kurosaki N, Takeuchi H, Nashimoto M, Takaku H. RNA cleavage by a mammalian tRNA 3′processing endoribonuclease (3′tRNase) reduces HIV-1 expression. Nucleic Acids Res Suppl 2002; (2): 297-8.
166. Kim MY, Jeong S. Inhibition of the functions of the nucleocapsid protein of human immunodeficiency virus-1 by an RNA aptamer. Biochem Biophys Res Commun 2004; 320: 1181-6.
167. Michienzi A, Castanotto D, Lee N, Li S, Zaia JA, Rossi JJ. RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci 2003; 1002: 63-71.
168. Ngok FK, Mitsuyasu RT, Macpherson JL, Boyd MP, Symonds GP, Amado RG. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol Biol 2004; 252: 581-98.
169. Bauer G, Valdez P, Kearns K, et al. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 1997; 89: 2259-67.
170. Leavitt MC, Yu M, Yamada O, et al. Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum Gene Ther 1994; 5: 1115-20.
171. Vandendriessche T, Chuah MK, Chiang L, Chang HK, Ensoli B, Morgan RA. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol 1995; 69: 4045-52.
172. Humeau LM, Binder GK, Lu X, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 2004; 9: 902-13.
173. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103: 17372-7.
174. Dropulic B. Lentivirus in the clinic. Mol Ther 2001; 4: 511-2.
175. Morgan RA, Walker R, Carter CS, et al. Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 2005; 16: 1065-74.
176. An DS, Donahue RE, Kamata M, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA 2007; 104: 13110-5.
177. Li MJ, Kim J, Li S, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-9.
178. Macpherson JL, Boyd MP, Arndt AJ, et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med 2005; 7: 552-64.
179. Zaia JA, Rossi JJ, Krishnan A, et al. Autologous stem cell transplantation using retrovirus-transduced peripheral blood progenitor cells in HIV-infected persons: comparison of gene marking post-engraftment with and without myeloablative therapy. Blood 1999; 94 (Suppl 1): 642a.
180. Wong-Staal F, Poeschla EM, Looney DJ. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1
181. Ranga U, Woffendin C, Verma S, et al. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci USA 1998; 95: 1201-6.